FDA fast tracks Friedreich’s ataxia drug undergoing testing in USF-led trial

The U.S. Food and Drug Administration yesterday designated fast-track status to EPI-743 for the treatment of Friedreich’s ataxia – a move that will help accelerate clinical development of […]